In a report released today, Jill Wu from CMB International Securities maintained a Buy rating on Thermo Fisher, with a price target of $553.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jill Wu’s rating is based on Thermo Fisher’s strong financial performance and strategic initiatives. The company reported a 3.0% year-over-year increase in revenue for the second quarter of 2025, surpassing Bloomberg’s consensus estimates. Despite slight declines in adjusted EPS, the results exceeded expectations, prompting management to raise the lower end of its full-year guidance. This reflects confidence in the company’s ability to navigate macroeconomic challenges and tariff impacts effectively.
Additionally, Thermo Fisher’s diverse segments, particularly in the pharma and biotech markets, showed robust growth, indicating a recovery in demand. The company’s strategic investments, such as a $2 billion plan to enhance U.S. manufacturing capabilities, position it well to capitalize on reshoring trends. With management’s optimistic long-term growth outlook and potential stabilization of industry headwinds, Jill Wu sees significant upside potential for Thermo Fisher, justifying the Buy rating.
Wu covers the Healthcare sector, focusing on stocks such as BeOne Medicines, Thermo Fisher, and Duality Biotherapeutics, Inc.. According to TipRanks, Wu has an average return of 38.9% and a 61.06% success rate on recommended stocks.
In another report released today, Scotiabank also maintained a Buy rating on the stock with a $590.00 price target.